AbCellera Biologics (ABCL) Assets Average (2021 - 2026)
AbCellera Biologics' (ABCL) quarterly Assets Average came in at $1.3 billion in Q1 2026, down 1.5% YoY from $1.4 billion in Q1 2025, and down 1.8% on a QoQ basis from $1.4 billion in Q4 2025.
AbCellera Biologics (ABCL) Assets Average (2021 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 6 years of Assets Average data on file, last reported at $1.3 billion in Q1 2026.
- Quarterly Assets Average fell 1.5% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (down 1.5% YoY) and the FY2025 annual result came in at $1.4 billion, down 4.6% from the prior year.
- Assets Average slipped to $1.3 billion in Q1 2026, from $1.4 billion in the prior quarter.
- In the past five years, Assets Average ranged from a high of $1.6 billion in Q2 2022 to a low of $1.3 billion in Q1 2026.
- A 5-year average of $1.5 billion and a median of $1.5 billion in 2022 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average soared 39.72% — and 2025, when it decreased 8.35%.
- Tracing ABCL's Assets Average over 5 years: stood at $1.5 billion in 2022, then declined by 3.01% to $1.5 billion in 2023, then slipped by 8.23% to $1.4 billion in 2024, then fell by 1.47% to $1.4 billion in 2025, then dropped by 1.8% to $1.3 billion in 2026.
- The last three Assets Average figures came in at $1.3 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | 1.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.31 Bn |
| Mar 31, 2026 | 1.33 Bn |
| Dec 31, 2025 | 1.36 Bn |
| Sep 30, 2025 | 1.38 Bn |
| Jun 30, 2025 | 1.37 Bn |
| Mar 31, 2025 | 1.35 Bn |
| Dec 31, 2024 | 1.38 Bn |
| Sep 30, 2024 | 1.40 Bn |
| Jun 30, 2024 | 1.44 Bn |
| Mar 31, 2024 | 1.48 Bn |
| Dec 31, 2023 | 1.50 Bn |
| Sep 30, 2023 | 1.52 Bn |
| Jun 30, 2023 | 1.52 Bn |
| Mar 31, 2023 | 1.52 Bn |
| Dec 31, 2022 | 1.55 Bn |
| Sep 30, 2022 | 1.57 Bn |
| Jun 30, 2022 | 1.59 Bn |
| Mar 31, 2022 | 1.46 Bn |
| Dec 31, 2021 | 1.25 Bn |
| Sep 30, 2021 | 1.16 Bn |